No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TNXP Tonix Pharmaceuticals
- 0.5440
- -0.0194-3.44%
Trading Jul 23 10:43 ET
9.50MMarket Cap-4P/E (TTM)
0.5650High0.5440Low453.05KVolume0.5650Open0.5634Pre Close251.32KTurnover2.60%Turnover RatioLossP/E (Static)17.45MShares36.160052wk High0.09P/B9.50MFloat Cap0.540952wk Low--Dividend TTM17.45MShs Float263679868.1600Historical High--Div YieldTTM3.73%Amplitude0.5400Historical Low0.5540Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Raises Price Target to $11
Tonix Pharmaceuticals Analyst Ratings
Express News | Tonix Pharmaceuticals Holding Corp : Alliance Global Partners Raises Target Price to $11 From $6
Express News | Tonix Pharmaceuticals Holding Corp -Set to File an Nda for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
Comments
$Tonix Pharmaceuticals(TNXP.US$
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Tonix Pharmaceuticals (NASDAQ:TNXP)is preparing to file a New Drug Application (NDA) for Tonmya, its fibromyalgia management drug, in the second half of 2024. The company anticipates FDA approval and commercial launch in the second half of 2025. Tonmya, a non-opioid sublingual tablet, has shown significant improvements in fibromyalgi...
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Tonix Pharmaceuticals (NASDAQ:TNXP)is preparing to file a New Drug Application (NDA) for Tonmya, its fibromyalgia management drug, in the second half of 2024. The company anticipates FDA approval and commercial launch in the second half of 2025. Tonmya, a non-opioid sublingual tablet, has shown significant improvements in fibromyalgi...
$Tonix Pharmaceuticals(TNXP.US$
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
1
$Tonix Pharmaceuticals(TNXP.US$ If their drug really profitable,a giant whale will aquire them like LLY aquire MORF.
$Tonix Pharmaceuticals(TNXP.US$ This drug actually haven fully approve by FDA but the big guy always make the news for investor to go in.Now they say that need to submit again by mid 2025 for production.I personally think there will be split share again.Maybe another 2 times.
$Tonix Pharmaceuticals(TNXP.US$ hi all why suddenly there is no premarket data for today....any news guys....mind share?
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg